phenoxymethylpenicillin Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
PENICILLIN V HYDRABAMINE, a semi-synthetic antibiotic, is used for the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) caused by susceptible, usually gram-positive, organisms.   NCATS

Chemistry

  • SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O
  • InChIKey: BPLBGHOLXOTWMN-MBNYWOFBSA-N
  • Mol. Mass: 350.4
  • ALogP: 0.7
  • ChEMBL Molecules:
    penicillin v  
    penicillin v potassium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.0161 - $0.3157

Australia

$0.0657 - $5.1170
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1- azabicyclo(3.2.0)heptane-2-carboxylic acid | (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | 6-phenoxyacetamidopenicillanic acid | beepen vk | beepen-vk | betapen-vk | fenoximetilpenicilina | ledercillin vk | meropenin | oracillin | penapar-vk | penicillin phenoxymethyl | penicillin potassium phenoxymethyl | penicillin v | penicillin vk | penicillin-vk | penicillin v potassium | pen-vee k | pfizerpen vk | phenomycilline | phenopenicillin | phenoxomethylpenicillin | phenoxymethylenepenicillinic acid | phenoxymethylpenicillin | phenoxymethyl penicillin | phénoxyméthylpénicilline | phenoxymethylpenicillinic acid | phenoxymethylpenicillin k | phenoxymethylpenicillin potassium | phenoxymethylpenicillinum | potassium phenoxymethyl penicillin | pv | uticillin vk | v-cillin | v-cillin k | v-cillin-k | veetids

Organizations (48)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (5)


 

Bacterial Infections (approved 1954)

Endocarditis

Pneumococcal Infections (approved 1990)

Staphylococcal Infections (approved 1990)

Streptococcal Infections (approved 1990)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Abscess (Phase 4)

Borrelia Infections (Phase 4)

Cellulitis (Phase 4)

Communicable Diseases (Phase 4)

Community-Acquired Infections (Phase 3)

COVID-19 (Phase 3)

Erythema (Phase 4)

Erythema Chronicum Migrans (Phase 4)

Healthy Volunteers (Phase 1)

Lyme Disease (Phase 4)

Penicillin V (Phase 1)

Peri-Implantitis (Phase 4)

Periodontal Diseases (Phase 4)

Pharyngitis (Phase 4)

Rheumatic Heart Disease (Phase 2)

Streptococcal Infections (Early Phase 1)

Tonsillitis (Phase 4)

Wound Infection (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue